It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective
Anniek Zaalberg1, Elisabeth Pottendorfer1, Wilbert Zwart1,2,3
1Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Abstract:
Prostate cancer is the second most common cancer in men worldwide and is associated with high morbidity and mortality. Consequently, there is an urgent unmet need for novel treatment avenues. In addition to somatic genetic alterations, deviations in the epigenetic landscape of cancer cells and their tumor microenvironment (TME) are critical drivers of prostate cancer initiation and progression. Unlike genomic mutations, epigenetic modifications are potentially reversible. Therefore, the inhibition of aberrant epigenetic modifications represents an attractive and exciting novel treatment strategy for castration-resistant prostate cancer patients. Moreover, drugs targeting the epigenome also exhibit synergistic interactions with conventional therapeutics by directly enhancing their anti-tumorigenic properties by "priming" the tumor and tumor microenvironment to increase drug sensitivity. This review summarizes the major epigenetic alterations in prostate cancer and its TME, and their involvement in prostate tumorigenesis, and discusses the impact of epigenome-targeted therapies.
Insights
Epigenetic alterations drive prostate cancer progression and are reversible targets. Epigenome-targeted therapies offer novel treatment strategies and enhance conventional drug efficacy for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Epigenetics
- Cancer Biology
Background:
- Prostate cancer is a leading cause of cancer-related death in men globally.
- Epigenetic modifications, alongside genetic alterations, significantly influence prostate cancer initiation and progression.
- The tumor microenvironment (TME) also exhibits epigenetic changes critical to cancer development.
Purpose of the Study:
- To review major epigenetic alterations in prostate cancer and its TME.
- To discuss the role of these epigenetic changes in prostate tumorigenesis.
- To explore the therapeutic potential of epigenome-targeted therapies.
Main Methods:
- Literature review of epigenetic alterations in prostate cancer.
- Analysis of the role of epigenetics in prostate cancer initiation and progression.
- Discussion of epigenome-targeted therapies and their synergistic effects.
Main Results:
- Aberrant epigenetic modifications are key drivers of prostate cancer.
- Epigenetic changes are present in both cancer cells and the TME.
- Epigenetic modifications are potentially reversible, offering therapeutic opportunities.
Conclusions:
- Inhibition of aberrant epigenetic modifications presents a promising therapeutic strategy for prostate cancer, particularly castration-resistant types.
- Epigenome-targeted drugs can enhance the efficacy of conventional treatments by sensitizing tumors.
- Targeting the epigenome represents an exciting new avenue for prostate cancer treatment.
Related Concept Videos
The Tumor Microenvironment
Epigenetic Regulation
X-chromosome...
Gene-Environment Interactions
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle


